| Time | Title | Name | Affilation |
|---|---|---|---|
| 08:00~08:30 | Registration | ||
| 08:30~08:40 | Opening remarks | Eui-Cheol Shin | KAI Immuno-Oncology Interest Group Leader |
| Session I. Cell-based cancer immunotherapy
Chair : Chang-Yuil Kang (Seoul National Univ.)
You-Me Kim (KAIST) |
|||
| 08:40~09:20 | Engineering Next Generation CAR T cells to Overcome Resistance | Crystal Mackall | Stanford Univ. |
| 09:20~10:00 | Understanding resistance to develop novel effective CART immunotherapies | Marco Ruella | Univ. of Pennsylvania |
| 10:00~10:20 | Coffee break | ||
| 10:20~10:50 | Adoptive CAST, cancer antigen-specific T cell, therapy | Byoung S. Kwon | Eutilex |
| 10:50~11:30 | CAR T Immunotherapy – Opportunities and Challenges | Stephan Grupp | Children's Hospital of Philadelphia |
| 11:30~12:00 | Luncheon symposium | CyTek Biosciences | |
| 12:00~13:20 | Lunch | ||
| Session II. Basic understanding of cancer immunotherapy
Chair : Eui-Cheol Shin (KAIST)
Hun Sik Kim (Univ. of Ulsan) |
|||
| 13:20~14:00 | Defining T Cell Exhaustion: Implications for Immunotherapy | Rafi Ahmed | Emory Univ. |
| 14:00~14:30 | Differentiation and function of Tc17 cells in tumor | Yeonseok Chung | Seoul National Univ. |
| 14:30~14:50 | Characteristics of tumor-infiltrating CD28null CD8+ T cells and their reinvigoration | Kyung Hwan Kim | KAIST |
| 14:50~15:10 | Plasticity of ILCs by tumor cells in lung tumor microenvironment | Jaemoon Koh | Seoul National Univ. |
| 15:10~15:50 | The role of CD8+ suppressor cell in regulating immunotherapy efficacy | Brian Gastman | Cleveland Clinic |
| 15:50~16:10 | Coffee break | ||
| Session III. Development and application of cancer immunotherapy
Chair : Joohyuk Sohn (Yonsei Univ.)
Tae Woo Kim (Korea Univ.) |
|||
| 16:10~16:40 | Hybrid Fc-fused interleukin-7 induces an inflamed tumor microenvironment and improves activity of cancer immunotherapy | Seung-Woo Lee | POSTECH |
| 16:40~17:20 | Emerging therapeutic antibodies in immuno-oncology | Jingwu Zang | I-Mab |
| 17:20~17:50 | ABL503, bispecific antibody targeting PD-L1 and 4-1BB: Strategic way to develop a next generation immunotherapy | Jaeho Jung | ABL Bio |
| 17:50~18:20 | Hyleukin-7 as T cell deficiency correcting drug in cancer therapy | Yun Jung Choi | Genexine |
| 18:20~18:30 | Closing remarks | ||
